Caliway’s drug molecule CBL-514 to treat Dercum’s disease receives EMA orphan drug designation: New Taipei City Thursday, November 14, 2024, 16:00 Hrs [IST] Caliway Biopharmac ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
In a similar manner, member states must now pool their resources to address their shared geoeconomic concerns. To achieve ...
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce ...
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...
EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of ...
Eseba-vec has received Fast Track Designation from the U.S. Food and Drug Administratin and PRIME designation from the European Medicines Agency for the treatment of 1L HPV16+ OPSCC. Eseba-vec was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback